PCN68 US AND CANADIAN COST-EFFECTIVENESS ANALYSES OF US ONCOLOGY TRIAL 9735 PROVIDE ADDITIONAL RATIONALE FOR AVOIDING ANTHRACYCLINES IN THE ADJUVANT TREATMENT OF OPERABLE BREAST CANCER
Oct 1, 2009, 00:00 AM
10.1016/S1098-3015(10)74319-9
https://www.valueinhealthjournal.com/article/S1098-3015(10)74319-9/fulltext
Section Title :
Section Order :
243
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)74319-9&doi=10.1016/S1098-3015(10)74319-9